Accessibility Menu
ThermoGenesis logo

ThermoGenesis(OTC) THMO

Market Cap$1.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-100%
5 YearN/A
1 Year+0%
1 Month+0%
$0.00
+0%
+0.00Today
ThermoGenesis last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-29
ThermoGenesis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-20
1 month+0%USD 0.002026-06-29
3 month+0%USD 0.002026-04-30
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-07-29
Since inception-100%USD 76,499.941992-05-01

ThermoGenesis Financials at a Glance

Market Cap

$1.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.61M

Net Income (TTM)

-$14.75M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.98 (Low)

Price

$0.00

Volume

1

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 14, 2026

THMO News

vir biotechnology

Why ThermoGenesis Stock Is Soaring Wednesday

James HalleyMar 15, 2023

Biotech Prospects for a Sizzling Summer

Mike HavrillaMay 16, 2007

Heads Up, Biotech Investors: Chapter 2

Mike HavrillaMay 2, 2007

ThermoGenesis Is Ready to Heat Up

Mike HavrillaApr 30, 2007

ThermoGenesis' Cold, Hard Cash

Rich SmithSep 11, 2006

Foolish Forecast: ThermoGenesis Begins

Rich SmithSep 5, 2006

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ThermoGenesis

ThermoGenesis Holdings, Inc. is a global innovator in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. Founded in 1986 and based in Rancho Cordova, California, the company offers advanced solutions for medical devices crucial for automated cell processing.

Products and Services
  • AXP II Automated Cell Separation System for isolating stem cells
  • BioArchive Automated Cryopreservation System for long-term storage
  • XP Point-of-Care System for rapid processing of autologous stem cells
Growth Outlook
  • Expansion into international markets, including China and the UAE
  • Increasing demand for cell-based therapies and bio-banking solutions
  • Focus on contract development and manufacturing services for gene therapies
Financial Highlights
  • Q1 2024 revenue of $2.74 million, up from $2.41 million in Q4 2023
  • Gross profit margin improved to 43.9% in Q1 2024
  • Cash and cash equivalents of $1.18 million as of March 31, 2024
ThermoGenesis Holdings, Inc. operates in the healthcare sector, specifically within the medical devices industry. The company has developed a robust portfolio of products that cater to the growing needs of cell processing and storage. The recent quarterly performance indicates a positive trend in revenue growth, with Q1 2024 showing an increase compared to the previous quarter. The improvement in gross profit margin reflects enhanced operational efficiency. With a focus on expanding into new markets and increasing demand for its innovative solutions, ThermoGenesis is well-positioned for future growth. The company's financial health, highlighted by its cash reserves, supports ongoing operations and potential expansion initiatives.
AI Generated • Jul 7, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

25

CEO

Xiao Chun Xu, PhD, EMBA

Website

www.thermogenesis.com

Headquarters

Rancho Cordova, CA 95742, US

THMO Financials

Key Financial Metrics (TTM)

Gross Margin

20.44%

Operating Margin

-69.60%

Net Income Margin

-190.31%

Return on Equity

-1367.44%

Return on Capital

-73.96%

Return on Assets

-160.03%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.85M

Volume

1

Avg. Volume

1.42K

Financials (TTM)

Gross Profit

$2.03M

Operating Income

-$6.09M

EBITDA

-$6.94M

Operating Cash Flow

-$3.61M

Capital Expenditure

-$982.00K

Free Cash Flow

-$4.59M

Cash & ST Invst.

$1.18M

Total Debt

$6.93M

ThermoGenesis Performance Analysis

ThermoGenesis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 9,294,000N/A
20222022-12-31USD 10,483,00012.8%
20232023-12-31USD 9,445,000-9.9%
ThermoGenesis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30-11.6%
Q32023-09-30-3.5%
Q42023-12-319.7%
Q12024-03-3113.8%
ThermoGenesis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -43.41N/A
20222022-12-31USD -20.45-52.9%
20232023-12-31USD -7.59-62.9%
ThermoGenesis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-3077.6%
Q32023-09-30-58.2%
Q42023-12-31-34.7%
Q12024-03-3176.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2024YOY CHG

Revenue

$2.74M

+6.4%

Gross Profit

$1.20M

+8.8%

Gross Margin

43.92%

N/A

Market Cap

$1.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$64.00

N/A

Employees

25

N/A

Net Income

-$1.86M

+63.5%

EBITDA

-$215.00K

+78.8%

Quarterly Fundamentals

Name
Q1 2024YOY CHG

Total Cash

$1.18M

-79.9%

Total Debt

$6.93M

-33.0%

Accounts Receivable

$1.15M

+20.3%

Inventory

$1.25M

-63.6%

Long Term Debt

$2.72M

-20.4%

Short Term Debt

$4.21M

-39.2%

Return on Assets

-1.60%

N/A

Return on Invested Capital

12.40%

N/A

Free Cash Flow

-$525.00K

+62.1%

Operating Cash Flow

-$505.00K

+17.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AAXTAamaxan Transport Group, Inc.
$0.00-0.00%
TBETTibet Pharmaceuticals, Inc.
$0.00+0.00%
NMTRQ9 Meters Biopharma, Inc.
$0.00+0.00%
OHAQOracle Healthcare Acquisition Corp.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About THMO

What is the current price of ThermoGenesis?

ThermoGenesis is trading at $0.00 per share.

What is the 52-week range for ThermoGenesis?

Over the past 52 weeks, ThermoGenesis has traded between $0.00 and $0.00.

How much debt does ThermoGenesis have?

As of the most recent reporting period, ThermoGenesis reported total debt of $11.28M.

How much cash does ThermoGenesis have on hand?

ThermoGenesis reported $2.00M in cash and cash equivalents in its most recent financial results.

What is ThermoGenesis’s dividend yield?

ThermoGenesis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services